Modest Survival Gain in Gastric/GEJ Cancer With Chemo Plus Pembrolizumab
Adding pembrolizumab (Keytruda) to chemotherapy modestly improved survival in unresectable/metastatic gastric or gastroesophageal junction (GEJ) cancer, a randomized trial showed. Median overall survival (OS) improved from 11.5 months with chemotherapy alone to 12.9 months with the addition of the immune checkpoint inhibitor. Median progression-free survival (PFS) improved from 5.6 months to 6.9 months. Landmark survival […]